Drugs / Ad-hCMV-TK
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06914479 | May 2026 → May 2031 expected | brain cancer, diffuse glioma, H3 G34 mutant | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT01811992 | Apr 2014 → Feb 2019 | glioblastoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-hCMV-TK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01811992 ↗ |
| Route | Other | “injections of adenoviral vectors expressing HSV1-TK and Flt3L into the tumour bed” PMID 37657463 ↗ Sep 2023 |